Bridgeway Capital Management LLC Has $25.18 Million Stock Position in Eli Lilly and Company $LLY

Bridgeway Capital Management LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 4.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 32,307 shares of the company’s stock after purchasing an additional 1,348 shares during the period. Eli Lilly and Company comprises approximately 0.6% of Bridgeway Capital Management LLC’s holdings, making the stock its 10th biggest holding. Bridgeway Capital Management LLC’s holdings in Eli Lilly and Company were worth $25,184,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Laurel Wealth Advisors LLC grew its position in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $8,827,714,000. Finally, Jennison Associates LLC increased its holdings in Eli Lilly and Company by 4.3% during the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after purchasing an additional 226,620 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on LLY shares. Truist Financial increased their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research report on Monday, December 1st. UBS Group raised their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,109.24.

Eli Lilly and Company Stock Up 1.8%

Shares of NYSE LLY opened at $1,027.68 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The firm’s 50-day moving average is $939.47 and its 200-day moving average is $818.98. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $971.55 billion, a PE ratio of 50.28, a price-to-earnings-growth ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.